Lokesh Jain, PhD
Advisor
Dr. Lokesh Jain is a seasoned drug development leader with extensive experience in early- and late-stage clinical programs. As Vice President of Clinical and Bioanalytical sciences at Merus NV, a biotech company in Cambridge MA, he oversees Translational Pharmacology, Clinical Pharmacology, Pharmacometrics and Bioanalysis functions for the entire Merus pipeline.
Prior to joining Merus, Dr. Jain led the Quantitative Pharmacology and Pharmacometrics (QP2) team which was responsible for Late-stage Oncology Portfolio at Merck focusing on Keytruda®. In that role, he provided scientific, strategic and operational oversight to worldwide regulatory submissions for pembrolizumab in 20+ indications, including submissions primarily based on modeling & simulation. He also oversaw multiple regulatory submissions for lenvatinib, olaparib, selumetinib, and belzutifan, which were jointly executed by Merck and external partners.
Before joining Merck, Dr. Jain served as a Team Leader in the Office of Clinical Pharmacology (OCP) at the FDA and a Research Associate in the National Cancer Institute (NCI) at the National Institutes of Health (NIH).
Dr. Jain has a strong publication record with 40+ peer reviewed publications, including in NEJM, JCO, CCR, PLoS
One, EJC, CPT, JCP CPT:PSP.
